|
|
|
| Effect of invigorating the spleen and kidney and dredging channels method combined with Prednisone in the treatment of progressive IgA nephropathy |
| XU Chao1，2 XIA Hong1 DENG Yueyi2 |
1.Department of Nephrology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou 310006, China;
2.Department of Nephrology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China |
|
|
|
Abstract Objective To study effect of invigorating the spleen and kidney and dredging channels method combined with Prednisone in the treatment of progressive IgA nephropathy (IgAN). Methods From January 2002 to March 2017, 69 patients with IgAN were selected from the Outpatient Department or Ward of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Among them, 37 patients treated with the method of invigorating the spleen and kidney and dredging channels were taken as Chinese medicine group, 32 patients treated with invigorating the spleen and kidney and dredging channels method combined with Prednisone were taken as Chinese and Western medicine group. The indexes of fasting serum creatinine, blood urea nitrogen, serum albumin, glomerular filtration rate, serum uric acid and 24 h urine protein were compared between two groups before and after treatment, and the curative effect of two groups was observed. Results After treatment, the serum creatinine and 24-h urinary protein of two groups were lower than before treatment, the serum albumin and glomerular filtration rate were higher than before treatment, the differences were statistically significant (P < 0.05). After treatment, the glomerular filtration rate of Chinese and Western medicine group was higher than that of Chinese medicine group, and the 24-h urine protein of Chinese and Western medicine group was lower than that of Chinese medicine group, the differences were statistically significant (P < 0.05). Total effective rate of Chinese and Western medicine group was higher than that of Chinese medicine group, the difference was statistically significant (P < 0.05). Conclusion Invigorating the spleen and kidney and dredging channels method combined with Prednisone can further stabilize the renal function of IgAN patients and reduce proteinuria.
|
|
|
|
|
|
[1] 王海燕.肾脏病学（精）[M].3版.北京：人民卫生出版社，2008：1002-1003.
[2] Xu X，Wang G，Chen N，et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China [J]. J Am Soc Nephrol，2016，27（12）：3739-3746.
[3] Wang J，Cui Z，Lu J，et al. Circulating antibodies against thrombospondin type-Ⅰ domain-containing 7A in Chinese patients with idiopathic membranous nephropathy [J]. Clin J Am Soc Nephrol，2017，12（10）：1642-1651.
[4] Lafayette RA，Kelepouris E. Immunoglobulin A nephropathy：advances in understanding of pathogenesis and treatment [J]. Am J Nephrol，2018，47（1）：43-52.
[5] Lai KN，Tang SC，Schena FP，et al. IgA nephropathy [J]. Nat Rev Dis Primers，2016，2：16001.
[6] Lv J，Zhang H，Wong MG，et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy：the TESTING randomized clinical trial [J]. Jama，2017，318（5）：432-442.
[7] Rauen T，Eitner F，Fitzner C，et al. Intensive supportive care plus immunosuppression in IgA nephropathy [J]. N Engl J Med，2015，373（23）：2225-2236.
[8] 中华人民共和国卫生部.中药新药临床研究指导原则[Z].1993.
[9] Lai KN，Lai FM，Ho CP，et al. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome： a long-term controlled trial [J]. Clin Nephrol，1986，26（4）：174-180.
[10] Welch TR，Fryer C，Shely E，et al. Double-blind，controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis [J]. J Pediatr，1992，121（3）：474-477.
[11] Fellstrom BC，Barratt J，Cook H，et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy（NEFIGAN）：a double-blind，randomised，placebo-controlled phase 2b trial [J]. Lancet （London，England），2017，389（10084）：2117-2127.
[12] Pozzi C. Treatment of IgA nephropathy [J]. J Nephrol，2016， 29（1）：21-25.
[13] Coppo R. Treatment of IgA nephropathy：recent advances and prospects [J]. Nephrol Ther，2018，14 Suppl 1：S13-S21.
[14] Ng R. Fish oil therapy in recurrent IgA nephropathy [J]. Ann Intern Med，2003，138（12）：1011-1012.
[15] Taji Y，Kuwahara T，Shikata S，et al. Meta-analysis of antiplatelet therapy for IgA nephropathy [J]. Clin Exp Nephrol，2006，10（4）：268-273.
[16] Feriozzi S，Polci R. The role of tonsillectomy in IgA nephropathy [J]. J Nephrol，2016，29（1）：13-19.
[17] 刘垠浩，陈丽贞，蓝元隆，等.补阳还五汤加减治疗IgA肾病35例临床观察[J].湖南中医杂志，2016，32（10）：68-70.
[18] 刘永芳，陈帮明，胡修全，等.通络保肾方治疗IgA肾病的临床研究[J].中国中西医结合肾病杂志，2016，17（11）：991-993.
[19] Rasche FM，Keller F，von Muller L，et al. Sequential immunosuppressive therapy in progressive IgA nephropathy [J]. Contrib Nephrol，2007，157：109-113.
[20] Ballardie FW. Quantitative appraisal of treatment options for IgA nephropathy [J]. J Am Soc Nephrol，2007，18（11）：2806-2809.
[21] Tam LS，Li EK，Wong CK，et al. Double-blind，randomized，placebo-controlledpilot study of leflunomide in systemic lupus erythematosus [J]. Lupus，2004，13（8）：601-604.
[22] Berthoux F，Mohey H，Laurent B，et al. Predicting the risk for dialysis or death in IgA nephropathy [J]. J Am Soc Nephrol，2011，22（4）：752-761.
[23] Al Hussain T，Hussein MH，Al Mana H，et al. Pathophysiology of IgA nephropathy [J]. Adv Anat Pathol，2017，24（1）：56-62.
[24] Reich HN，Troyanov S，Scholey JW，et al. Remission of proteinuria improves prognosis in IgA nephropathy [J]. J Am Soc Nephrol，2007，18（12）：3177-3183.
[25] 聂莉芳，徐建龙，余仁欢，等.IgA肾病中医临床实践指南概览[J].中国中西医结合肾病杂志，2013，14（7）：565-567.
[26] 王永钧.难治性肾病综合征的中西医结合治疗[J].浙江中医学院学报，2000，24（1）：48-50.
[27] Mao XQ，Yu F，Wang N，et al. Hypoglycemic effect of polysaccharide enriched extract of Astragalus membranaceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism [J]. Phytomedicine，2009，16（5）：416-425.
[28] 王建新.黄精降糖降脂作用的实验研究[J].中国中医药现代远程教育，2009，7（1）：93-94. |
|
|
|
